Epiregulin expression by Ets-1 and ERK signaling pathway in Ki-ras-transformed cells

Biochemical and Biophysical Research Communications

Volumn 377, Issue 3, 2008, Pages 832-837

  Cho, Min Chul ^a   Choi, Hee Sook ^a   Lee, Sojung ^a   Kim, Bo Yeon ^b   Jung, Mira ^c   Park, Sue Nie ^d   Yoon, Do Young ^a  

^a Konkuk University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Korea Food and Drug Administration   (South Korea)

Author keywords

Epiregulin; Ets 1; Ki ras; Oncogene; Prosate cancer; RAF MEK ERK pathway

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BETA TUBULIN; EPIREGULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RAF PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; ONCOGENE KI RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; PROMOTER REGIONS, GENETIC; PROSTATE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEIN C-ETS-1; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 56249098213     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.053     Document Type: Article

References (26)

1. Toyoda H., Komurasaki T., Uchida D., Takayama Y., Isobe T., Okuyama T., and Hanada K. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 270 (1995) 7495-7500
2. Komurasaki T., Toyoda H., Uchida D., and Morimoto S. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-2 and ErbB-4. Oncogene 15 (1997) 2841-2848
3. Shirakata Y., Komurasaki T., Toyoda H., Hanakawa Y., Yamasaki K., Tokumaru S., Sayama K., and Hashimoto K. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J. Biol. Chem. 275 (2000) 5748-5753
4. Zhu Z., Kleeff J., Friess H., Wang L., Zimmermann A., Yarden Y., Buchler M.W., and Korc M. Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem. Biophys. Res. Commun. 273 (2000) 1019-1024
5. Baba I., Shirasawa S., Iwamoto R., Okumura K., Tsunoda T., Nishioka M., Fukuyama K., Yamamoto K., Mekada E., and Sasazuki T. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaing pathway in human colon cancer cells. Cancer Res. 60 (2000) 6886-6889
6. Lindvall C., Hou T., Komurasaki M., Zheng C., Henriksson M., Sedivy J.M., Bjorkholm M., The B.T., Nordenskjold M., and Xu D. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res. 63 (2003) 1743-1747
7. Nicholson B.E., Frierson H.F., Conaway M.R., Seraj J.M., Harding M.A., Hampton G.M., and Theodorescu D. Profiling the evolution of human metastatic bladder cancer. Cancer Res. 64 (2004) 7813-7821
8. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., Gomis R.R., Manova-Todorova K., and Massangue J. Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature 446 (2007) 765-770
9. Yan J., Roy S., Apolloni A., Lane A., and Hancock J.F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 273 (1998) 24052-24056
10. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., Franklin R.A., and McCubrey J.A. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17 (2003) 1263-1293
11. Leprince D., Gegonne A., Coll J., de Taisne C., Schneeberger A., Lagrou C., and Stehelin D. A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature 306 (1983) 395-397
12. Karim F.D., Urness L.D., Thummel C.S., Klemsz M.J., McKercher S.R., Celada A., Van Beveren C., Maki R.A., Gunther C.V., and Nye J.A. The ETS-domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence. Gene Dev. 49 (1990) 1451-1453
13. Seth A., and Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 41 (2005) 2462-2478
14. Alipov G., Nakayama T., Ito M., Kawai K., Naito S., Nakashima M., Niino D., and Sekine I. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 46 (2005) 202-208
15. Sementchenko V.I., Schweinfest C.W., Papas T.S., and Watson D.K. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 17 (1998) 2883-2888
16. Yang B.S., Hauser C.A., Henkel G., Colman M.S., Van Beveren C., Stacey K.J., Hume D.A., Maki R.A., and Ostrowski M.C. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol. 16 (1996) 538-547
17. Watabe T., Yoshida K., Shindoh M., Kaya M., Fujikawa K., Sato H., Seiki M., Ishii S., and Fujinaga K. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor, Int. J. Cancer 77 (1998) 128-137
18. Parda D.S., Thraves P.J., Kuettel M.R., Lee M.S., Arnstein P., Kaighn M.E., Rhim J.S., and Dritschilo A. Neoplastic transformation of a human prostate epithelial cell line by the v-ki-ras oncogene. Prostate 23 (1993) 91-98
19. Kim B.Y., Gaynor R.B., Dritschilo A., and Jung M. Constitutive activation of NF-kB in Ki-ras-transformed prostate epithelial cells. Oncogene 21 (2002) 4490-4497
20. Spencer V.A., Sun J.M., Li L., and Davie J.R. Chromatin immunoprecipitation: a tool for studying histone acetylation and transcription factor binding. Methods 31 (2003) 67-75
21. Shang Y., Hu X., DiRenzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
22. Schulze A., Nicke B., Warne P.H., Tomlinson S., and Downward J. The transcriptional response to Raf activation is almost completely dependent on mitogen-activated protein kinase kinase activity and shows a major autocrine component. Mol. Biol. Cell 15 (2004) 3450-3463
23. Behrens P., Rothe M., Wellmann A., Krischler J., and Wernert N. The Ets-1 transcription factor is up-regulated together with MMP1 and MMP9 in the stroma of pre-invasive breast cancer. J. Pathol. 194 (2001) 43-50
24. Dittmer J. The biology of the Ets-1 proto-oncogene. Mol. Cancer 2 (2003) 29
25. Ornskov D., Nexo E., and Sorensen B.S. Real-time polymerase chain reaction is a sensitive and precise method for quantifying transcription from reporter plasmids. Scand. J. Clin. Lab. Invest. 64 (2004) 723-728
26. Nye J.A., Petersen J.M., Gunther C.V., Jonsen M.D., and Graves B.J. Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev. 6 (1992) 975-990